| 晚期乳腺癌一线内分泌治疗联合贝伐珠单抗未能获得生存获益 |
| |
| 引用本文： | 林颖,邵楠,任重阳. 晚期乳腺癌一线内分泌治疗联合贝伐珠单抗未能获得生存获益[J]. 循证医学, 2015, 15(3): 141-143. DOI: 10.3969/j.issn.1671-5144.2015.03.007 |
| |
| 作者姓名： | 林颖 邵楠 任重阳 |
| |
| 作者单位： | 1. 中山大学附属第一医院乳腺病诊治中心, 广州 510080; 2. 广东省人民医院肿瘤中心乳腺科、广东省医学科学院, 广州 510080 |
| |
| 摘 要： | 1文献来源Martín M,Loibl S,von Minckwitz G,et al.Instituto de Investigación Sanitaria Gregorio Mara觡ón,Universidad Complutense.PhaseⅢtrial evaluating the addition of Bevacizumab to endocrine therapy asfirst-line treatment for advanced breast cancer:The Letrozole/Fulvestrant and Avastin(LEA)study[J].J Clin Oncol,2015,33(9):1045-1052.2证据水平1b。3背景激素受体阳性转移性乳腺癌首选内分泌治疗,内分泌治疗联合靶向药物有可能延迟甚至逆
|
| 关 键 词： | 晚期乳腺癌 贝伐珠单抗 内分泌治疗 无进展生存期 总生存期 |
Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer Cannot Increase in Survival |
| |
| LIN Ying,SHAO Nan,REN Chong-yang. Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer Cannot Increase in Survival[J]. The Journal of Evidence-Based Medicine, 2015, 15(3): 141-143. DOI: 10.3969/j.issn.1671-5144.2015.03.007 |
| |
| Authors: | LIN Ying SHAO Nan REN Chong-yang |
| |
| Affiliation: | Reviewer’s address：Center of Diagnosis and Treatment of Breast Diseases, The First Hospital Affiliated of Sun Yat-sen University, Guangzhou 510080, China |
| |
| Abstract: | |
| |
| Keywords: | advanced breast cancer Bevacizumab endocrine therapy progression-free survival overall survival |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《循证医学》浏览原始摘要信息 |
|
点击此处可从《循证医学》下载全文 |
